What are your top takeaways in GI Cancers from ESMO 2025?

1. MATTERHORN Study

The global phase III MATTERHORN trial enrolled 474 patients with resectable gastric or gastroesophageal junction adenocarcinoma, randomized to receive FLOT alone or FLOT plus durvalumab. The primary endpoint, event-free survival (EFS), was previously reported as positive. Adding d...

The new results from CheckMate 8HW confirmed an ORR of 73% vs 61%, with a “not reached” median duration of response. Importantly, I note that the time to response is 2.8 months. The confirmed and updated PFS at 4 years is 64% vs 49%. The OS at 4 years is 78% vs 65%. BREAKWATER at ASCO 2025 cemented ...

1. Updated data on the MATTERHORN study confirms an OS benefit and that all patients benefit, even the 15% with PD-L1 negative tumors

2. The PHERFLOT study: a 50% pCR rate for the combination of pre-operative pembrolizumab/trastuzumab and FLOT, at the expense of a 40% grade 3 diarrhea rate.

3. FORTITU...